Overview of innovation
The bottleneck to most of the molecular (PCR) testing is due to lack of nucleic acid extraction kits. Where available, the possibility of automation enhances the speed with which one can access high throughput extraction. Therefore, development and manufacture of efficient extraction reagents is the first step towards pandemic/infectious disease outbreak readiness. The lessons from Covid-19 outbreak should include countries readying themselves against such outbreaks by manufacturing their own reagents and having the ability to ramp up production when necessary. Our product development and manufacturing is one such step towards self sufficiency in infectious disease readiness.
Name of Developer
Phiyani Lebea
Primary Organisation
Tokabio (Pty) Ltd
Was this innovation co-created?
Innovation Area/Category
Technology Readiness Level
Technology readiness level 7
Intellectual Property
Type of Intellectual Property protection
Know how
Trade secret
Opportunity Type